Second annual Molecular Analysis for Research and Diagnostics
February 13-14, 2002 o San Diego, California
Immediately following CHI's Seventh Annual Gene Quantification
The growing momentum of genomics and molecular analysis has enormous
promise for earlier and non (or less) invasive diagnostics, novel
therapeutics and more precise prognoses in cancer, cardiovascular and
infectious diseases. Improved patient stratification holds the allure
of faster, smaller clinical trials and fewer adverse effects for
patients. Advances in gene sequencing and analysis have made these
processes higher throughput, more scaleable and reproducible.
Microarrays are revolutionizing basic research. Proteomics and
protein chips further broaden the range of possibilities.
But the diagnostics industry sector is an intensely competitive,
cost-sensitive one. DNA/RNA diagnostics are perceived are slow,
expensive and labor intensive. Biological and regulatory challenges
are formidable. Thorny ethical and social issues are unresolved, and
clinicians, patients - and society have little background to prepare
them to understand or utilize truly new paradigms.
Session topics may include
· Biomarkers, surrogate markers
· Identification of unknown gene mutations
· Insights into gene functions, cellular processes, pathways and
· Industrializing molecular analysis
· Clinical applications
Researchers are encouraged to submit proposals for oral (or poster)
presentation. Proposals from endusers and proposals comparing or
integrating technologies are particularly encouraged.
Please submit proposals (and suggestions for speakers) by e-mail or
Mary Chitty, Conference Director
e-mail: mchitty at healthtech.com
For full consideration, please submit by August 3, 2001
The 2001 program is at http://www.healthtech.com/2001/gdx/index.htm